ClinicalTrials.gg
RecruitingNCT05687292Updated May 12, 2026

Application of a Clinical Decision Support System to Reduce Mechanical Ventilation Duration After Cardiac Surgery in Children

An observational study in Congenital Heart Disease, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 1 Day to 12 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Boston Children's Hospital · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
330
Ages
1 Day to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Heart Defects, Congenital by Boston Children's Hospital — 9 open to participants now, 10 under way, none of them phase 3. Heart Defects, Congenital · Boston Children's Hospital.

Planned enrollment
Largest of 19
330 · median 64
Started
2024
with 1 other
Observational
19 of 37
8 open now
Registered
31st of 37
by date

Among the 37 studies in Heart Defects, Congenital by Boston Children's Hospital, this one has the largest planned enrollment of the 19 observational ones that give a count, is one of 2 that started in 2024, is one of 19 observational ones, and was the 31st registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

9 of the 37 studies in Heart Defects, Congenital by Boston Children's Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 1 Day to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Heart Defects, Congenital by Boston Children's Hospital, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the impact of a clinical decision support system (CDSS) in children receiving mechanical ventilation (MV) after surgery for congenital heart disease (CHD). The main question it aims to answer is:

-What is the impact of a CDSS designed to facilitate weaning and discontinuation of MV on the duration of MV in post-operative congenital cardiac surgery patients?

Participants will be identified as eligible to initiate weaning from mechanical ventilation. Providers will decide whether or not to initiate weaning based on recommendations provided by the CDSS. Researchers will compare patients exposed to the CDSS with a historical cohort to see if the CDSS facilitated a decrease in MV duration.

Read the detailed description

Prolonged mechanical ventilation (MV) in children with congenital heart disease (CHD) is associated with morbidity and mortality. There is no standard approach to weaning MV in CHD patients. Similarly, extubation failure is associated with morbidity and mortality, and there is no existing method for predicting extubation success in CHD patients. The overarching aim of this study is to use a novel clinical decision support system (CDSS) informed by continuous data streams and risk analytics algorithms to facilitate shorter MV duration.

The CDSS will be built into the T3 Visualization Platform (T3). T3 continuously tracks all inputs from a patient's existing physiologic monitors, ventilator, and laboratory values from the electronic medical record. T3 then graphically displays the data on a single bedside computer/monitor that is updated every 5 seconds. The platform includes three FDA 510(k)-cleared predictive analytics algorithms for estimating the risk of low cardiac output (IDO2), inadequate ventilation (IVCO2), and acidosis (IPH). The investigators for this study have previously evaluated IDO2 and IVCO2 in a retrospective cohort of children receiving MV for greater than or equal to 48 hours following cardiac surgery. This study identified that patients with a low IDO2 and IVCO2 had a higher probability of remaining extubated without the need for reintubation or unplanned use of noninvasive ventilation in the 48 hours following extubation.

The CDSS will be designed to prompt discussion around timing of ventilator weaning, extubation readiness assessments, and extubation. Recommendations will be informed by the continuous monitoring of a patient and based on trends in vital signs and the risk analytics algorithms.

This study will be a single center, nonrandomized before and after study with additional quasi-experimental design component using interrupted time-series analysis (with retrospective evaluation of pre-intervention and prospective data collection post-intervention).

03

Conditions studied

  • Congenital Heart Disease

Keywords

  • cardiac surgery
  • congenital heart disease
  • critical care
  • pediatrics
  • mechanical ventilation
04

Who can participate

Ages eligible
1 Day to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Neonates, infants, and children with congenital heart disease receiving mechanical ventilation after cardiac surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children \< 12 years old
  • Post-cardiac surgery
  • Receiving mechanical ventilation for ≥ 48 hours in the Cardiac Intensive Care Unit at Boston Children's Hospital following surgery

Exclusion criteria

Exclusion Criteria:

  • Premature infants (\<37 weeks' gestation)
  • Weight \< 2kg
  • Baseline ventilator (via tracheostomy) or noninvasive positive pressure dependence
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
330 participants (estimated)
Patient registry
No

Groups and cohorts

  • CDSS Ventilator Weaning Group

    This group will be exposed to the CDSS to inform weaning and discontinuation of mechanical ventilation.

    Device: Clinical decision support system (CDSS) for ventilator weaning

Interventions

  • DeviceClinical decision support system (CDSS) for ventilator weaning

    A clinical decision support system (CDSS) will be integrated into a software program (the T3 platform) that is present on all patient bedside computers. The T3 platform is a tool that compiles data from a patient's existing physiologic monitors, ventilator, and laboratory results and graphically displays them on a bedside monitor. The CDSS will be active on all patients receiving mechanical ventilation, but primary use and evaluation will focus on patients meeting study criteria. Twice daily (on morning rounds and evening rounds), patients will be screened for eligibility. During each rounds, teams will review the CDSS and associated risk analytics data used to inform the associated recommendations for ventilator weaning, extubation readiness assessment, and extubation. The clinical team will consider the CDSS in decision making around ventilator weans. If the decision is made not to follow the CDSS recommendations, the clinician will complete a brief survey with rationale.

06

What researchers measure

Primary outcomes

  1. Duration of Mechanical Ventilation

    Measured in days; Obtained from date/time of initial extubation minus date/time of admission from surgery, divided by 24 to give an exact determination of days

    Time frame: Up to 28 days after surgery

Secondary outcomes

  1. Unplanned extubation

    Unplanned extubation during CDSS activation; Occurring between return from surgery and initial planned extubation

    Time frame: From date of surgery until date of first documented extubation, assessed up to 28 days

  2. Unplanned use of noninvasive ventilation

    Patient extubated to room air requiring escalation to positive pressure ventilation

    Time frame: Within 48 hours of extubation

  3. Unplanned reintubation

    Patient requires unplanned replacement of breathing tube

    Time frame: Within 48 hours of extubation

  4. Adherence rate by clinical team to CDSS recommendations

    Clinical team follows recommendations provided by the CDSS for ventilator weaning, extubation readiness test performance, and extubation

    Time frame: From date of CDSS initiation until date of first documented extubation, assessed up to 28 days

Other outcomes

  1. Cardiac intensive care unit length of stay

    Measured in days

    Time frame: From date of surgery until the date of initial discharge from the cardiac intensive care unit, assessed up to 52 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.

Of 178 non-industry observational studies under Heart Defects, Congenital, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 24 months is below that.

Counting every sponsor, half of 185 studies reached it within 44 months; a quarter within 17 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2022
First posted
Jan 18, 2023
StartActual
Nov 18, 2024
Primary completionEst.
Nov 18, 2026
CompletionEst.
Mar 1, 2027
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05687292
Collaborators
The Brett Boyer Foundation
Responsible party
Taylor M Smith (Principal Investigator, Boston Children's Hospital) — Principal investigator
First posted
Jan 18, 2023
Start date
Nov 18, 2024
Primary completion
Nov 18, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
May 12, 2026

Study contacts

Daniel L Hames, MD
Contact
daniel.hames@cardio.chboston.org
6173554023
Daniel Hames, MD
principal investigator · Boston Children's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion